课件：恶性嗜铬细胞瘤的治疗.ppt

* * Alternative of Current Therapy Surgery Radiopharmaceuticals Combined Chemotherapy Transcatheter Arterial Embolization * * TAE has been successfully performed in the treatment of malignant PCC with liver metastases The therapeutic effects of TAE have been demonstrated to be enhanced by the combination therapy with anticancer chemotherapy * * Mitomycin C has been successfully used in TAE for liver metastasis in several cases of malignant PCC. * * * * Malignant pheochromocytoma: past, present and future Past Present Future Adrenergic blockers, α-methyl-paratyrosine use of other drugs for symptomatic relief Surgical debulking; 131I-MIBG radiotherapy; Chemotherapy; Chemoembolization Molecular targeting, cancer vaccines, gene therapy 后面内容直接删除就行 资料可以编辑修改使用 资料可以编辑修改使用 资料仅供参考，实际情况实际分析 主要经营：课件设计，文档制作，网络软件设计、图文设计制作、发布广告等 秉着以优质的服务对待每一位客户，做到让客户满意！ 致力于数据挖掘，合同简历、论文写作、PPT设计、计划书、策划案、学习课件、各类模板等方方面面，打造全网一站式需求 * size was not significantly different between malignant pheochromocytomas without local invasion or metastases and benign pheochromocytomas (6.1 ± 3.1 cm vs 5.3 ± 2.3 cm). * * * Therapy of Malignant Pheochromocytoma恶性嗜铬细胞瘤的治疗 Literature Report * * Introduction rule of 10s for pheochromocytoma (PCC) 10% bilateral 10% extra-adrenal 10% extra-abdomen 10% malignant 10% familial 10% children 10% normal blood pressure * * Introduction The most frequent site of metastases is the skeleton Additional sites are liver, retroperitoneum with lymph nodes, CNS, pleura, and kidney * * Malignant vs. Benign Currently, there is no effective cure for malignant pheochromocytoma. There are also no reliable histopathological methods for distinguishing benign from malignant tumors. Malignancy requires evidence of metastases at non-chromaffin sites distant from that of the primary tumor. * * Metastatic disease in pheochromocytoma may be present at the time of initial diagnosis or may only became eviden